Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use
| Autor: | R. Bruce Sloane, Kerrin White, Ruby Palmer, Eric Frederickson, George M. Simpson, Edmond Pi |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Blood Platelets
Depressive Disorder Dose-Response Relationship Drug business.industry Tranylcypromine Mao activity Pharmacology Enzyme inhibition Time course Phenethylamines Selegiline medicine Antidepressant Humans Monoamine oxidase B Phenelzine Platelet monoamine oxidase business Monoamine Oxidase Biological Psychiatry medicine.drug |
| Zdroj: | Biological psychiatry. 20(6) |
| ISSN: | 0006-3223 |
| Popis: | From the Medical College of Pennsylvania at Eastern Pennsylvania Psychiatric Institute (G.M.S., E.P.), Philadelphia, PA; the University of Southern California School of Medicine, Department of Psychiatry and the Behavioral Sciences (E.F., R.P., R.B.S.), Los Angeles, CA; and McLean Hospital CK.W.), Belmont, MA. Address reprint requests to Dr. George M. Simpson, Eastern Pennsylvania Psychiatric Institute, 3200 Henry Avenue, Philadelphia, PA 19129. Received April 19, 1984; revised December 20, 1984. treatment. For example, the work of Robinson et al. (1978) and Georgotas et al. (1983) with phenelzine has suggested that antidepressant effects occur with dosages of about 1 mg/kg/day, or platelet MAO inhibition of >80%, and that the time course of enzyme inhibition parallels that of clinical improvement. However, MAOIs have other effects besides enzyme inhibition, and it is far from clear that this is the mechanism of overriding therapeutic importance (Hendley and Snyder 1968; Karoum et al. 1982). Even if it were, the key variable would presumably be brain MAO activity, and the use of platelet MAO as a model would still pose problems, For example, platelet MAO is almost exclusively of the B type, which is pref |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|